1977

• First clinical use of the ATG-Fresenius^® S polyclonal antibody in organ transplantation

1983

• First marketing approval of ATG-Fresenius^® S in Germany, additional countries follow

1989

• First clinical use of the ATG-Fresenius^® S polyclonal antibody in stem cell transplantation

2001 

• First clinical use of Removab^® (INN: Catumaxomab)

2003

• Fresenius Biotech GmbH founded
• First clinical use of Rexomun^® (INN: Ertumaxomab)

2004

• EU Commission grants orphan drug status to Removab (INN: Catumaxomab) for ovarian carcinoma

2006 

• EU Commission grants orphan drug status to Removab (INN: Catumaxomab) for gastric carcinoma 
• FDA (US Food and Drug Administration) grants orphan drug status to Removab® (INN: Catumaxomab) for ovarian carcinoma

2008

• FDA grants orphan drug status to ATG-Fresenius^® S as prophylaxis against rejection reactions in organ transplantations

2009

• EU Commission grants marketing approval for Removab (INN: Catumaxomab) for the treatment of patients with malignant ascites
• FDA grants orphan drug status to Removab (INN: Catumaxomab) for gastric carcinoma